Biotech, Pharmaceutical and Clinical Research Jobs | BioSpace

Pictured: Eric Dube, Travere CEO/Company Courtesy

Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks

The company’s treatment for IgA nephropathy, sparsentan, failed to meet statistical significance by a measure of kidney function in a head-to-head confirmatory study versus irbesartan.

Pictured: A yellow line pointing the way out of a

Mesoblast Sees Path Forward for Twice-Rejected Cell Therapy After FDA Meeting

Following a Type A meeting with the regulator, the biotech says it has clarity about the next steps in demonstrating remestemcel-L’s effectiveness in acute graft-versus-host disease.

Pictured: FDA signage at its office in Washington,

Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar

Pictured: Capsules in a production line at a pharm

Civica Rx’s Unique Business Model Improves Drug Supply Security, Cuts Costs: Study

Pictured: Genentech Headquarters/iStock, Sundry Ph

Genentech Doubles Down with Orionis Deal Worth up to $2B for Glue Degraders

More Top Stories

View all Featured Employers

Sequence’s new training facility/Sequence

New Training Models Address Workforce Gap in Biopharma Manufacturing

Business people networking/iStock, Hero Images

Biopharma Career Fairs Make a Powerful Comeback

Two scientists collaborating in a laboratory_iStoc

Postdoc Programs at Pharmaceutical Companies: A Research Path Less Chosen

Pictured: Eric Dube, Travere CEO/Company Courtesy

9/21/2023

Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks

Pictured: A yellow line pointing the way out of a

9/21/2023

Mesoblast Sees Path Forward for Twice-Rejected Cell Therapy After FDA Meeting

Pictured: FDA signage at its office in Washington,

9/21/2023

Third Time Might Be a Charm for Alvotech as FDA Accepts BLA for Humira Biosimilar

Pictured: Capsules in a production line at a pharm

9/21/2023

Civica Rx’s Unique Business Model Improves Drug Supply Security, Cuts Costs: Study

Pictured: Genentech Headquarters/iStock, Sundry Ph

9/21/2023

Genentech Doubles Down with Orionis Deal Worth up to $2B for Glue Degraders

View all Hotbeds

Pictured: Eric Dube, Travere CEO/Company Courtesy

9/21/2023

Travere’s Kidney Disease Drug Narrowly Misses Phase III Endpoint, Stock Tanks

Pictured: FDA sign in its headquarters/iStock, Gra

9/20/2023

Taysha Drops Gene Therapy Candidate as FDA Again Calls for Study Changes

Pictured: FDA Sign/Grandbrothers/Adobe Stock

9/20/2023

FDA Decisions 2023: ARS Pharma, GSK, Iovance and More

Pictured: Astellas Illinois Headquarters/iStock, J

9/19/2023

Astellas Touts Izervay Phase III Geographic Atrophy Data, Eyes Label Expansion

Sequence’s new training facility/Sequence

New Training Models Address Workforce Gap in Biopharma Manufacturing

Biopharma Layoff Tracker 2023: NightHawk, Fresh Tracks, Histogen and More Cut Staff

Pictured: Moderna Headquarters/iStock, hapabapa

Moderna Scales Back COVID Vaccine Production, Pursues mRNA Medicines Plan

Pictured: Syringe drawing up vaccine/iStock, Diy13

Moderna, Pfizer-BioNTech’s Updated COVID-19 Vaccines Approved by FDA

Benchmarking Paid Time Off

Recruiting with AI: Trends and Challenges in Life Sciences

Recruiting with AI: Trends and Challenges in Life Sciences

U.S. Life Sciences Salary Report

Best Places to Work in Biopharma